BioStem Technologies Inc. (BSEM) Next Earnings Date & Expected ±12.5% Move

Per the Roarable RQD rating, BSEM scores 35 out of 100, a letter grade of D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 11/20 (ROIC of -5.7% and FCF yield of 0%); Whale 13F Flow at 3/20 (institutional accumulation and options positioning); Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 6/20 (beta of 1.0 and sector sensitivity); and Forensic Balance Sheet at 10/20 (Altman Z 2.44, Piotroski F 5/9, Debt/Equity 0.5). For a prospective investor, the weakest pillar is institutional flow at 3/20, indicating little visible institutional support in the source data, while the fundamental cash engine's negative ROIC and zero FCF yield limit near-term upside drivers. The forensic balance sheet is the relative strength within a weak profile, with an Altman Z of 2.44 and a Debt/Equity of 0.5. Valuation tradeoffs cannot be fully assessed because P/E and EV/EBITDA are not available in source data, and the recent price decline of -14.57% sits against a 52-week range of $1.11 - $8.4, meaning the shares trade near the low end of their annual band.

BioStem Technologies Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry, per the company profile. Per the SEC financials, the company reported revenue of $47.5M for FY 2025, down from $69.7M in FY 2024. The source data does not specify its product lines, customer base, or detailed revenue model.

Per the SEC financials, the company moved from positive operating and net income in FY 2024 to losses in FY 2025, with net margin of -13.9% and operating margin of -1.5% in the market data section, against a gross margin of 93.6%. ROIC is -5.7%. Per the Roarable RQD rating, the Altman Z-Score is 2.44 and the Piotroski F-Score is 5/9. The Debt/Equity ratio is 0.5, and reported cash rose to $29.5M in FY 2025, though debt figures are not available in source data.

Per the recent news wire, several items concern insider option exercises: the COO was reported as exercising options to acquire 250,000 shares at $2 per share, and the CEO and COO together were reported as investing $1 million in cash through option exercises. A separate report states the CEO exercised options for 250,000 shares at $2 per share. Third-quarter results are scheduled for release on Nov. 12, with management discussing them at 4:30 p.m. ET. An SEC filing dated Oct 13, 2026 is also referenced. Each news item is rated YELLOW by the source feed. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals, so no additional sector signals are available.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore not available in source data. A prospective investor should note that the absence of mapped links means ripple effects from suppliers, customers, or peer companies cannot be assessed from these sources.

• What are the company's current debt obligations, given that debt is listed as N/A in both reported periods?
• What drove the swing from $31.0M net income in FY 2024 to $-6.6M in FY 2025, and what is the revenue mix behind the $69.7M to $47.5M decline?
• What is the reported EPS, since the source lists EPS as N/A for both periods?
• Will the Nov. 12 third-quarter results confirm or change the FY 2025 loss trajectory?
• What is the purpose and disclosure context of the insider option exercises relative to the current share price?